Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-1.23
EPS est.
$-1.22
EPS surprise
-0.82%
1-day move
+4.27%
Crinetics Pharmaceuticals reported a narrower loss per share than expected, which may have contributed to the positive stock reaction. However, the lack of revenue and guidance leaves uncertainty about future performance. Investors may be cautiously optimistic due to the slight EPS beat, but the absence of revenue figures raises questions.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.23 | $-1.24 | +0.82% |
| Revenue | — | $9M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for endocrine diseases and metabolic disorders. With a market cap of $4 billion, its work in pharmaceuticals is crucial as it addresses unmet medical needs in these specialized areas.
Last quarter
In Q4 2025, Crinetics reported an EPS of $-1.29, slightly better than the expected $-1.37, indicating a small positive surprise. However, revenue details were not disclosed, leaving some uncertainty about sales performance.
EPS beat streak
1Q
EPS beat rate
38%
Avg EPS surprise
-1.40%
Avg 1-day reaction
+1.19%
Analysts expect Crinetics to report a loss of $-1.24 per share on revenues of $9 million for Q1 2026. The market is closely watching these figures to gauge the company's progress in its drug development pipeline.
Bull case
If Crinetics can exceed revenue expectations and show signs of progress in its clinical trials, it could lead to a positive market reaction and increased investor confidence.
Bear case
Conversely, if the company reports a wider loss than expected or fails to provide clarity on its drug development progress, it could lead to a negative reaction from investors.
Key metrics to watch
EPS
$-1.24Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$9MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
What is the expected revenue for Q1 2026 and how does it compare to the consensus of $9 million?
Revenue performance will be a key indicator of market demand for Crinetics' products and its overall financial health.
Q2
What updates can management provide on the progress of its drug development pipeline?
Investors will be looking for clarity on the company's future prospects and any potential catalysts that could drive growth.
—
Est. EPS
$0.97
Est. Rev
$754M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may be underestimating the potential for Crinetics to exceed revenue expectations due to recent positive trends in its drug pipeline.
Supporting evidence
The company has a history of surprising analysts with better-than-expected EPS, as seen in the last quarter.
The options market is pricing in a significant move, suggesting that traders anticipate volatility and potential positive news.
Key risk
If revenue comes in significantly above $9 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's results will hinge on revenue performance and updates on drug development, which are critical for investor confidence.
Bull confirmed if
Reporting revenue above $9 million and demonstrating progress in clinical trials would confirm the bull case.
Bear confirmed if
A wider loss than the expected $-1.24 EPS would confirm the bear case.
What the market is pricing for the move.
Implied Move
±10.7%
Historical Avg
±2.3%
The options market is pricing in a significant move of about 10.7%, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±21.6% while CRNX has averaged ±2.3% over the last 8 prints — setup is pricing rich.
30d HV
44.2%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 3.9%, with a raw directional average of +1.9% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
119.21%
of float
Insider
1.13%
of float
Holders
386
institutions
Top Holders· as of Jun 2026
FMR, LLC
15,840,219 sh · $1.3B
14.93%
0.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Crinetics beats expectations, history suggests the stock could rise by about 1.42%, confirming a positive outlook.
In line / cautious
A cautious in-line report may lead to a muted response, reflecting uncertainty in the market.
Miss
If the company misses expectations, history suggests a potential decline of around 0.71%, indicating investor disappointment.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Blackrock Inc.
9,758,938 sh · $829.0M
9.20%
15.1%
Farallon Capital Management LLC
8,989,098 sh · $763.6M
8.47%
7.8%
Wellington Management Group, LLP
7,131,084 sh · $605.8M
6.72%
-12.6%
Driehaus Capital Management, LLC
6,463,551 sh · $549.1M
6.09%
1.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Jul 30, 2026 · disclosed Sep 4, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.